Nasopharyngitis (Common Cold) Therapeutic and Drug Pipeline Review H2

.

.

Nasopharyngitis (Common Cold) - Pipeline Review, H1 2017

PUNE, INDIA, March 17, 2017 /EINPresswire.com/ -- Nasopharyngitis (Common Cold) - Pipeline Review, H1 2017

Summary
Nasopharyngitis also known as common cold is an infectious, inflammatory condition that affects the throat and nasal passages. The virus can spread through droplets in the air when someone who is sick coughs, sneezes or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1056674-nasopharyngitis-common-cold-pipeline-review-h1-2017

Report Highlights
This report provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration and Preclinical stages are 2 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.
Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantageAdditionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Nasopharyngitis (Common Cold) - Overview
Nasopharyngitis (Common Cold) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Nasopharyngitis (Common Cold) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nasopharyngitis (Common Cold) - Companies Involved in Therapeutics Development
Charleston Laboratories Inc
Orbis Biosciences Inc
Vernalis Plc
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1056674-nasopharyngitis-common-cold-pipeline-review-h1-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.